4517.TSE · Biofermin Pharmaceutical Co., Ltd

-

Please sign in to comment on 4517.TSE

1 Comment

Admin

4 years ago

Biofermin Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 9.1% above its 200 day moving average.

From a valuation standpoint, the stock is 95.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.1.

Biofermin Pharmaceutical Co., Ltd's total revenue sank by 11.4% to $3B since the same quarter in the previous year.

Its net income has dropped by 40.8% to $516M since the same quarter in the previous year.

Based on the above factors, Biofermin Pharmaceutical Co., Ltd gets an overall score of 2/5.

Exchange	TSE
CurrencyCode	JPY
Sector	Healthcare
ISIN	JP3799800002
Industry	Drug Manufacturers - Specialty & Generic

Beta	0.21
PE Ratio	24.23
Market Cap	37B
Target Price	None
Dividend Yield	2.3%

ABOUT

Biofermin Pharmaceutical Co., Ltd

Biofermin Pharmaceutical Co., Ltd. manufactures and sells drugs and quasi-drugs in Japan. It offers drugs for the treatment of diarrhea, constipation, and stomach digestion; and veterinary medicines, pesticides and other chemicals, cosmetics, medical equipment, foods, beverages, food additives, feeds, feed additives, and various tests. The company was formerly known as Kobe hygiene Laboratory Co., Ltd. and changed its name to Biofermin Pharmaceutical Co., Ltd. in March 1949. The company was founded in 1917 and is headquartered in Kobe, Japan. Biofermin Pharmaceutical Co., Ltd. is a subsidiary of Taisho Pharmaceutical Holdings Co., Ltd.

4517.TSE · Biofermin Pharmaceutical Co., Ltd

-

Biofermin Pharmaceutical Co., Ltd

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Biofermin Pharmaceutical Co., Ltd using a moving average strategy